Zhejiang Conba Pharmaceutical Co.,Ltd. predicted a yearly growth of 70% for net profit attributable to shareholders in the first three quarters of 2013, due to increasing sales revenue that has boosted prime operating profit.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.29 CNY | -0.75% | +2.12% | +4.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.75% | 1.88B | |
+21.59% | 44.15B | |
+23.03% | 23.02B | |
+18.22% | 15.33B | |
+12.26% | 13.74B | |
+52.55% | 12.16B | |
-10.02% | 6.84B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.88% | 5.66B |
- Stock Market
- Equities
- 600572 Stock
- News Zhejiang CONBA Pharmaceutical Co.,Ltd.
- Zhejiang Conba Pharmaceutical Co.,Ltd. Provides Earnings Guidance the First Nine Months of 2013